Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Agile Therapeutics, Inc., a women`s healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Website: agiletherapeutics.com



Growth: Bad revenue growth rate 0.0%, there is slowdown compared to average historical growth rates 104.2%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -39.1%. On average the margin is improving steadily. Gross margin is high, +73.2%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$9.38 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 459.3% higher than minimum and 57.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.4x by EV / Sales multiple , the company can be 32.5% undervalued

Key Financials (Download financials)

Ticker: AGRX
Share price, USD:  (0.0%)1.51
year average price 1.5100  


year start price 1.5100 2025-06-12

max close price 1.5100 2025-06-12

min close price 1.5100 2025-06-12

current price 1.5100 2026-06-12
Common stocks: 41 232 562

Dividend Yield:  0.0%
EV / Sales: 2.6x
Margin (EBITDA LTM / Revenue): -39.1%
Fundamental value created in LTM:
Market Cap ($m): 62
Net Debt ($m): -3
EV (Enterprise Value): 59
Price to Book: -2.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-21GlobeNewsWire

Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024

2024-03-20GlobeNewsWire

Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024

2023-09-28The Motley Fool

Why Shares of Agile Therapeutics Jumped This Week

2023-05-12Seeking Alpha

Agile Therapeutics, Inc. (AGRX) Q1 2023 Earnings Call Transcript

2023-05-08GlobeNewsWire

Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-08-12 2024-05-15 2023-11-09 2023-08-09 2023-05-11 2022-11-07
acceptedDate 2024-08-12 16:30:28 2024-05-15 16:30:55 2024-03-28 16:31:37 2023-11-09 16:30:51 2023-08-09 16:31:01 2023-05-11 16:20:49 2023-03-22 19:33:01 2022-11-07 16:20:43 2022-03-30 16:28:37 2021-03-01 16:15:53 2020-02-20 16:36:47
calendarYear 2024 2024 2023 2023 2023 2022
period Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
revenue 6M 6M 20M 7M 6M 4M 11M 3M 4M 749 000 0
costOfRevenue 1M 2M 9M 2M 2M 2M 7M 1M 11M 282 000 163 000
grossProfit 4M 4M 11M 4M 3M 2M 4M 2M -7M 467 000 -163 000
grossProfitRatio 0.732 0.706 0.628 0.581 0.475 0.525
researchAndDevelopmentExpenses 538 000 495 000 2M 705 000 703 000 763 000 3M 788 000 6M 14M 10M
generalAndAdministrativeExpenses 3M 3M 11M 3M 3M 3M 12M 3M 15M 13M 9M
sellingAndMarketingExpenses 4M 4M 18M 5M 5M 5M 30M 6M 43M 23M 0
sellingGeneralAndAdministrativeExpenses 6M 6M 28M 7M 8M 8M 42M 8M 58M 36M 9M
otherExpenses 0 0 0 0 0 0 0 0 0 0 0
operatingExpenses 7M 7M 30M 8M 8M 9M 45M 9M 64M 50M 19M
costAndExpenses 8M 8M 39M 11M 11M 11M 52M 11M 75M 50M 19M
interestIncome 28 000 23 000 78 000 13 000 15 000 33 000 80 000 46 000 25 000 309 000 252 000
interestExpense 0 185 000 1M -341 000 372 000 402 000 3M 1M 4M 3M 0
depreciationAndAmortization 0 103 000 386 000 98 000 95 000 33 000 2M 308 000 2M 276 000 163 000
ebitda -3M 2M -13M -4M -5M -7M -25M -7M -65M -48M -19M
ebitdaratio -0.492 0.275 -0.6 -0.912 -1.751 -2.424
operatingIncome -3M -3M -20M -4M -5M -7M -41M -8M -71M -49M -19M
operatingIncomeRatio -0.492 -0.482 -0.6 -0.931 -1.759 -2.527
totalOtherIncomeExpensesNet -9M 4M 5M 3M 2M 1M 11M -12M -62 000 -3M 252 000
incomeBeforeTax -12M 1M -14M -799 000 -4M -5M -30M -20M -75M -52M -19M
incomeBeforeTaxRatio -2.129 0.225 -0.12 -0.692 -1.414 -6.551
incomeTaxExpense 0 0 0 -98 000 372 000 -2M -5M 2M 2M 0 -163 000
netIncome -12M 1M -14M -799 000 -4M -4M -25M -22M -77M -55M -18M
netIncomeRatio -2.129 0.225 -0.12 -0.692 -0.947 -7.345
eps -1.73 0.28 -6.71 -0.27 -2.15 -3.96 -58.79 -29.8 -63 115 -1291.56 -746.2
epsdiluted -1.73 0.28 -0.27 -2.15 -3.96 -29.8
weightedAverageShsOut 7M 5M 2M 3M 2M 912 044 432 218 739 956 1213.411 42 341 24 716
weightedAverageShsOutDil 7M 5M 2M 3M 2M 912 044 432 218 739 956 1213.411 42 341 24 716
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link
filingDate 2024-03-28 2023-03-23 2022-03-30 2021-03-01 2020-02-20
fiscalYear 2023 2022 2021 2020 2019
netInterestIncome -1M -3M -4M -3M 252 000
ebit -13M -27M -67M -49M -19M
nonOperatingIncomeExcludingInterest -7M -14M -4M -309 000 0
netIncomeFromContinuingOperations -14M -25M -71M -52M -18M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 -163 000
netIncomeDeductions 0 0 0 0 -163 000
bottomLineNetIncome -14M -25M -71M -52M -18M
epsDiluted -6.71 -58.79 -63 115 -1291.56 -746.2

Balance Sheet Statement

Property 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-08-12 2024-05-15 2023-11-09 2023-08-09 2023-05-11 2022-11-07
acceptedDate 2024-08-12 16:30:28 2024-05-15 16:30:55 2024-03-28 16:31:37 2023-11-09 16:30:51 2023-08-09 16:31:01 2023-05-11 16:20:49 2023-03-22 19:33:01 2022-11-07 16:20:43 2022-03-30 16:28:37 2021-03-01 16:15:53 2020-02-20 16:36:47
calendarYear 2024 2024 2023 2023 2023 2022
period Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
cashAndCashEquivalents 3M 3M 3M 3M 3M 4M 5M 6M 19M 14M 34M
shortTermInvestments 0 0 0 0 0 0 0 0 0 40M 0
cashAndShortTermInvestments 3M 3M 3M 3M 3M 4M 5M 6M 19M 54M 34M
netReceivables 5M 5M 3M 4M 4M 3M 3M 4M 2M 865 000 0
inventory 6M 4M 3M 2M 3M 2M 1M 2M 966 000 0 0
otherCurrentAssets 1M 811 000 402 000 562 000 898 000 1M 1M 3M 2M 769 000 840 000
totalCurrentAssets 14M 12M 10M 10M 12M 11M 11M 15M 24M 57M 35M
propertyPlantEquipmentNet 282 000 385 000 487 000 587 000 684 000 779 000 872 000 964 000 13M 14M 14M
goodwill 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 238 000 238 000 238 000 238 000 238 000 2M 2M 2M 2M 2M 177 000
totalNonCurrentAssets 520 000 623 000 725 000 825 000 922 000 3M 3M 3M 15M 16M 14M
otherAssets 0 0 0 0 0 0 0 0 0 0 0
totalAssets 15M 13M 10M 11M 13M 14M 14M 18M 39M 73M 50M
accountPayables 17M 13M 10M 7M 6M 10M 8M 5M 9M 4M 2M
shortTermDebt 289 000 378 000 2M 2M 2M 2M 1M 2M 17M 0 172 000
taxPayables 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 9M 8M 832 000 8M 7M 6M 833 000 5M 2M 2M 2M
totalCurrentLiabilities 26M 21M 21M 18M 15M 19M 13M 12M 29M 7M 4M
longTermDebt 0 0 0 196 000 288 000 378 000 0 550 000 0 16M 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 11M 1M 6M 6M 9M 4M 6M -6M 0 0 0
totalNonCurrentLiabilities 11M 1M 6M 6M 9M 5M 6M 550 000 784 000 16M 0
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 289 000 378 000 466 000 549 000 630 000 708 000 785 000 827 000 959 000 138 000 0
totalLiabilities 37M 23M 27M 23M 25M 23M 20M 12M 30M 24M 4M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 5000 5000 4000 0 0 0 4000 4000 12 000 9000 7000
retainedEarnings -434M -422M -423M -419M -418M -414M -409M -431M -387M -312M -260M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0 3000 0
othertotalStockholdersEquity 412M 412M 406M 406M 405M 437M
totalStockholdersEquity -22M -10M -16M -12M -12M -9M -6M 6M 9M 49M 46M
totalEquity -22M -10M -16M -12M -12M -9M -6M 6M 9M 49M 46M
totalLiabilitiesAndStockholdersEquity 15M 13M 11M 13M 14M 18M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 15M 13M 10M 11M 13M 14M 14M 18M 39M 73M 50M
totalInvestments 0 0 0 0 0 0 0 0 0 40M 0
totalDebt 289 000 378 000 2M 3M 3M 2M 2M 2M 18M 17M 172 000
netDebt -3M -2M -385 000 -356 000 -91 000 -2M -3M -4M -1M 2M -34M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link
filingDate 2024-03-28 2023-03-23 2022-03-30 2021-03-01 2020-02-20
fiscalYear 2023 2022 2021 2020 2019
accountsReceivables 3M 3M 2M 865 000 0
otherReceivables 0 0 0 0 0
prepaids 441 000 0 775 000 680 000 0
totalPayables 10M 8M 9M 4M 2M
otherPayables 0 0 0 0 0
accruedExpenses 8M 3M 1M 2M 0
capitalLeaseObligationsCurrent 366 000 319 000 175 000 138 000 0
capitalLeaseObligationsNonCurrent 100 000 466 000 784 000 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 407M 403M 387M 362M 0
otherTotalStockholdersEquity 0 -4000 9M 0 306M

Cash Flow Statement

Property 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4 2019 q4
date 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31 2019-12-31
symbol AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX AGRX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-08-12 2024-05-15 2023-11-09 2023-08-09 2023-05-11 2022-11-07
acceptedDate 2024-08-12 16:30:28 2024-05-15 16:30:55 2024-03-28 16:31:37 2023-11-09 16:30:51 2023-08-09 16:31:01 2023-05-11 16:20:49 2023-03-22 19:33:01 2022-11-07 16:20:43 2022-03-30 16:28:37 2021-03-01 16:15:53 2020-02-20 16:36:47
calendarYear 2024 2024 2023 2023 2023 2022
period Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY FY
netIncome -12M 1M -14M -798 000 -4M -5M -25M -20M -75M -52M -19M
depreciationAndAmortization 102 000 103 000 386 000 98 000 95 000 93 000 2M 262 000 2M 276 000 163 000
deferredIncomeTax 0 0 -6M -4M -2M 0 0 0 5M 0 -711 000
stockBasedCompensation 285 000 333 000 2M 439 000 481 000 498 000 2M 536 000 3M 3M 2M
changeInWorkingCapital 3M -128 000 7M 4M -4M 5M -2M -10M -3M 107 000 992 000
accountsReceivables 263 000 -1M -15 000 940 000 -1M 254 000 -2M -2M -668 000 -865 000 0
inventory -2M -1M -2M 125 000 -325 000 -879 000 -366 000 543 000 -6M -4M 0
accountsPayables 0 2M 0 2M -4M 5M -628 000 -6M 5M 4M 1M
otherWorkingCapital 0 0 10M 526 000 2M -4M 705 000 -3M -1M 972 000 -385 000
otherNonCashItems 0 135 000 1M 252 000 279 000 -1M -12M 12M 2M 1M 711 000
netCashProvidedByOperatingActivities 233 000 -2M -10M 365 000 -9M -2M -36M -17M -65M -47M -16M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 -133 000 -126 000 -269 000 -353 000 -98 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 353 000 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 -55M 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 40M 15M 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 -126 000
debtRepayment 0 -2M -348 000 -286 000 -225 000 -12M
commonStockIssued 0 0 70 000 7M 1M 22M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 4M 0 0 0 0
netCashUsedProvidedByFinancingActivities 0 3M -278 000 7M 778 000 10M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 233 000 59 000 -3M 88 000 -2M -817 000 -14M -7M 5M -20M 27M
cashAtEndOfPeriod 3M 3M 3M 3M 3M 4M 5M 6M 19M 14M 34M
cashAtBeginningOfPeriod 3M 3M 5M 3M 4M 5M 19M 13M 14M 34M 8M
operatingCashFlow 233 000 -2M -10M 365 000 -9M -2M -36M -17M -65M -47M -16M
capitalExpenditure 0 0 0 0 0 0 -133 000 -126 000 -269 000 -353 000 -98 000
freeCashFlow 233 000 -2M -10M 365 000 -9M -2M -36M -17M -65M -48M -16M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link
filingDate 2024-03-28 2023-03-23 2022-03-30 2021-03-01 2020-02-20
fiscalYear 2023 2022 2021 2020 2019
otherInvestingActivities 0 -133 000 40M -353 000 -147 000
netCashProvidedByInvestingActivities 0 -133 000 39M -41M -98 000
netDebtIssuance -1M -17M 0 20M 0
longTermNetDebtIssuance -975 000 -17M 0 20M 0
shortTermNetDebtIssuance -372 000 0 0 0 0
netStockIssuance 8M 40M 30M 48M 0
netCommonStockIssuance 8M 35M 30M 48M 0
commonStockIssuance 8M 35M 30M 48M 42M
netPreferredStockIssuance 0 4M 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 15M 0 75 000 -449 000 42M
netCashProvidedByFinancingActivities 7M 22M 30M 68M 42M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2023 q4
2024-03-28 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-12 ET (fiscal 2023 q1)
2022 q4
2023-03-24 ET (fiscal 2022 q4)
2022 q3
2022-11-07 ET (fiscal 2022 q3)
2022 q2
2022-08-11 ET (fiscal 2022 q2)
2022 q1
2022-05-12 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-06-26 ET
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
2024-05-15 ET
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-03-28 12:05 ET
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
2024-03-25 20:30 ET
Agile Therapeutics Announces Delisting from Nasdaq
2024-03-21 10:35 ET
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
2024-03-20 12:15 ET
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
2024-03-13 11:31 ET
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
2024-02-22 14:01 ET
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
2024-02-22 ET
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
2024-02-15 21:30 ET
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
2024-01-23 14:29 ET
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
2023-12-12 13:01 ET
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
2023-11-22 14:00 ET
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
2023-11-09 13:05 ET
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-26 12:05 ET
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
2023-10-04 20:30 ET
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
2023-09-28 13:00 ET
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
2023-09-28 ET
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
2023-09-05 12:05 ET
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-17 13:00 ET
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
2023-08-17 ET
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
2023-08-09 12:05 ET
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-26 12:30 ET
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
2023-07-19 13:00 ET
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
2023-07-18 13:00 ET
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
2023-07-11 13:15 ET
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage
2023-07-05 13:00 ET
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
2023-07-05 ET
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
2023-07-03 13:00 ET
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
2023-07-03 ET
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
2023-06-30 13:00 ET
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?
2023-06-28 13:00 ET
The Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care
2023-06-26 12:01 ET
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
2023-06-23 16:05 ET
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
2023-06-15 20:05 ET
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
2023-06-13 20:05 ET
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
2023-05-25 20:05 ET
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
2023-05-25 ET
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
2023-05-23 00:00 ET
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
2023-05-22 ET
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
2023-05-11 20:05 ET
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
2023-05-08 12:00 ET
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
2023-04-28 12:01 ET
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
2023-04-26 13:01 ET
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
2023-04-10 20:30 ET
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
2023-03-22 20:05 ET
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
2023-03-21 13:05 ET
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
2023-02-27 13:31 ET
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
2023-02-15 13:00 ET
Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer
2023-02-09 13:00 ET
Corium Pharma Solutions Names Two Industry Veterans to its Executive Team
2023-02-01 13:01 ET
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
2023-01-26 21:30 ET
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
2023-01-20 13:45 ET
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
2023-01-20 ET
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
2023-01-09 12:00 ET
Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
2022-12-21 14:05 ET
This Biotech Company is Pursuing Positive Cash Flow In 2023
2022-12-01 13:30 ET
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
2022-11-15 13:15 ET
Women’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
2022-11-07 21:05 ET
Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-10-26 12:30 ET
Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
2022-10-26 12:00 ET
Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?
2022-10-21 15:00 ET
NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022
2022-10-21 ET
NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022
2022-10-07 20:25 ET
Agile Therapeutics Announces Reorganization of Leadership Team
2022-09-06 12:30 ET
Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
2022-08-11 20:05 ET
Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-07-28 12:05 ET
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
2022-07-12 12:05 ET
Agile Therapeutics Updates Second Quarter 2022 Guidance
2022-07-08 12:05 ET
Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel
2022-07-06 21:16 ET
Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
2022-07-06 ET
Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
2022-07-01 13:20 ET
Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering
2022-07-01 ET
Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering
2022-05-17 12:01 ET
Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
2022-05-12 20:05 ET
Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-05-05 21:01 ET
Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
2022-05-03 11:30 ET
Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022
2022-04-26 12:00 ET
Agile Therapeutics Announces 1-For-40 Reverse Stock Split
2022-04-14 11:30 ET
Agile Therapeutics Announces First Quarter 2022 Prescription Data for Twirla®
2022-04-11 11:05 ET
Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Development Program
2022-04-11 ET
Agile Therapeutics Receives $4.7M After Selling Net Operating Loss Tax Benefits Through New Jersey Economic Development Program
2022-04-07 11:30 ET
Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)
2022-03-31 11:30 ET
Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z
2022-03-30 20:05 ET
Agile Therapeutics Reports Fourth Quarter & Full Year 2021 Financial Results and Provides Corporate Update
2022-03-14 12:00 ET
Agile Therapeutics Announces $4.85 Million Registered Direct Offering
2022-03-14 ET
Agile Therapeutics Announces $4.85 Million Registered Direct Offering
2022-03-11 13:01 ET
Agile Therapeutics to Participate in Upcoming March Investor Events
2022-03-07 13:01 ET
Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Wednesday, March 30, 2022
2022-01-12 22:29 ET
Agile Therapeutics Acknowledges New Government Guidance Reinforcing Requirement to Cover Contraceptives that a Woman and Her Heathcare Provider Determine are Medically Appropriate at No Cost
2022-01-10 13:01 ET
Agile Therapeutics and Afaxys Partner to Expand Access to Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System
2022-01-05 13:03 ET
Agile Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
2022-01-05 13:01 ET
Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences
2021-11-02 20:05 ET
Agile Therapeutics Reports Third Quarter 2021 Financial Results
2021-10-22 12:01 ET
Agile Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on Tuesday, November 2, 2021
2021-10-12 12:01 ET
Agile Therapeutics Applauds Congressional Chairs’ Letter to Biden Administration Requesting Enforcement of Contraceptive Access Under Affordable Care Act
2021-10-08 20:05 ET
Agile Therapeutics Appoints Josephine Torrente to its Board of Directors
2021-10-08 12:30 ET
Agile Therapeutics Announces Pricing of $22,666,650 Underwritten Public Offering of Common Stock and Warrants
2021-10-08 ET
Agile Therapeutics Announces Pricing of $22,666,650 Underwritten Public Offering of Common Stock and Warrants
2021-10-07 20:05 ET
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Warrants
2021-10-04 12:02 ET
Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal Formulary
2021-09-28 18:52 ET
Agile Therapeutics Partners with Carli Lloyd, U.S. Women’s Soccer Star and Four-Time Olympian, to Bring Awareness to Women’s Health Topics
2021-09-28 12:01 ET
Agile Therapeutics Partners with Carli Lloyd, U.S. Women’s Soccer Star and Four-Time Olympian, to Bring Awareness to Women’s Health Topics
2021-09-07 11:30 ET
Agile Therapeutics to Participate in Upcoming Investor Conferences
2021-08-20 11:30 ET
Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
2021-07-26 20:05 ET
Agile Therapeutics Reports Second Quarter 2021 Financial Results
2021-07-01 12:05 ET
Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021
2021-05-26 12:05 ET
Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference
2021-05-12 12:00 ET
Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference
2021-05-04 20:05 ET
Agile Therapeutics Reports First Quarter 2021 Financial Results
2021-04-30 15:01 ET
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting
2021-04-20 14:56 ET
CORRECTING AND REPLACING -- Agile Therapeutics
2021-04-20 13:30 ET
Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020
2021-03-05 12:30 ET
Agile Therapeutics to Present at Upcoming March Investor Conferences
2021-03-01 21:05 ET
Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors
2021-02-19 13:35 ET
Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Monday, March 1, 2021
2021-01-04 17:18 ET
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
2020-12-21 12:30 ET
Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-07 12:30 ET
Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch
2020-11-30 14:11 ET
Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception
2020-11-23 15:00 ET
Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
2020-11-12 21:05 ET
Agile Therapeutics Reports Third Quarter 2020 Financial Results
2020-11-04 12:30 ET
Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020
2020-09-22 15:40 ET
Agile Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
2020-09-09 12:00 ET
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
2020-09-08 12:00 ET
Agile Therapeutics Announces Virtual Investor/Analyst Day on Monday, September 21, 2020
2020-09-02 13:00 ET
Agile Therapeutics Launches I’m So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control
2020-08-17 12:00 ET
Agile Therapeutics Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Chief Medical Officer
2020-08-11 20:02 ET
Agile Therapeutics to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference
2020-08-11 20:01 ET
Agile Therapeutics Reports Second Quarter 2020 Financial Results
2020-07-21 11:30 ET
Agile Therapeutics to Host Second Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, August 11, 2020
2020-06-16 12:00 ET
Agile Therapeutics to Join Russell 3000® and 2000® Indexes
2020-05-11 20:05 ET
Agile Therapeutics to Participate in Virtual Fireside Chat as part of the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020
2020-05-05 20:01 ET
Agile Therapeutics Reports First Quarter 2020 Financial Results
2020-04-23 11:30 ET
Agile Therapeutics to Host First Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, May 5, 2020
2020-04-22 12:00 ET
Agile Therapeutics Announces Changes to its Board of Directors
2020-02-25 16:41 ET
Agile Therapeutics, Inc. (Nasdaq: AGRX) to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020
2020-02-21 13:35 ET
Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock
2020-02-20 21:14 ET
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
2020-02-20 21:01 ET
Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-14 23:46 ET
FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin
2020-02-10 21:30 ET
Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors
2020-01-06 13:00 ET
Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco
2020-01-02 13:00 ET
Agile Therapeutics Strengthens Commercial Leadership Team
2019-12-19 21:05 ET
Agile Therapeutics to Present at Biotech Showcase™ 2020 in San Francisco
2019-11-14 21:30 ET
Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
2019-10-30 22:33 ET
Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)
2019-10-28 12:00 ET
Agile Therapeutics Reports Third Quarter 2019 Financial Results
2019-03-12 20:15 ET
Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
2019-03-11 08:00 ET
Agile Therapeutics to Present at Upcoming Investor Conferences
2019-03-04 12:30 ET
Agile Therapeutics Announces $7.8 Million Private Placement

SEC forms

Show financial reports only

SEC form 10
2024-08-12 00:00 ET
Agile Therapeutics reported for 2024 q2
SEC form 8
2024-05-15 00:00 ET
Agile Therapeutics published news for 2024 q1
SEC form 8
2024-05-15 00:00 ET
Agile Therapeutics reported for 2024 q1
SEC form 10
2024-05-15 00:00 ET
Agile Therapeutics reported for 2024 q1
SEC form 8
2024-04-09 00:00 ET
Agile Therapeutics published news for 2024 q1
SEC form 8
2024-04-09 00:00 ET
Agile Therapeutics published news for 2024 q1
SEC form 10
2024-03-28 16:31 ET
Agile Therapeutics reported for 2023 q4
SEC form 8
2024-03-28 09:06 ET
Agile Therapeutics reported for 2023 q4
SEC form 8
2024-03-28 09:06 ET
Agile Therapeutics published news for 2023 q4
SEC form 10
2024-03-28 00:00 ET
Agile Therapeutics reported for 2023 q4
SEC form 10
2023-11-09 16:30 ET
Agile Therapeutics reported for 2023 q3
SEC form 8
2023-11-09 08:15 ET
Agile Therapeutics published news for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Agile Therapeutics reported for 2023 q3
SEC form 10
2023-08-09 16:31 ET
Agile Therapeutics reported for 2023 q2
SEC form 6
2023-08-09 08:10 ET
Agile Therapeutics reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Agile Therapeutics reported for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Agile Therapeutics reported for 2023 q2
SEC form 6
2023-06-30 16:50 ET
Agile Therapeutics published news for 2023 q1
SEC form 6
2023-06-27 16:46 ET
Agile Therapeutics published news for 2023 q1
SEC form 6
2023-06-14 16:35 ET
Agile Therapeutics published news for 2023 q1
SEC form 6
2023-06-08 16:35 ET
Agile Therapeutics published news for 2023 q1
SEC form 6
2023-06-05 08:30 ET
Agile Therapeutics published news for 2023 q1
SEC form 10
2023-05-11 16:20 ET
Agile Therapeutics reported for 2023 q1
SEC form 6
2023-05-11 16:15 ET
Agile Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Agile Therapeutics reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Agile Therapeutics reported for 2023 q1
SEC form 6
2023-04-28 16:40 ET
Agile Therapeutics published news for 2023 q1
SEC form 6
2023-04-28 10:38 ET
Agile Therapeutics published news for 2023 q1
SEC form 8
2023-04-28 00:00 ET
Agile Therapeutics published news for 2023 q1
SEC form 6
2023-04-26 16:59 ET
Agile Therapeutics published news for 2023 q1
SEC form 6
2023-04-10 17:16 ET
Agile Therapeutics published news for 2023 q1
SEC form 6
2023-03-30 16:35 ET
Agile Therapeutics published news for 2022 q4
SEC form 10
2023-03-23 00:00 ET
Agile Therapeutics published news for 2022 q4
SEC form 10
2023-03-22 19:33 ET
Agile Therapeutics published news for 2022 q4
SEC form 6
2023-03-22 16:15 ET
Agile Therapeutics reported for 2022 q4
SEC form 8
2023-03-22 00:00 ET
Agile Therapeutics reported for 2022 q4
SEC form 6
2023-03-14 16:29 ET
Agile Therapeutics published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Agile Therapeutics published news for 2022 q4
SEC form 10
2022-11-07 00:00 ET
Agile Therapeutics reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Agile Therapeutics reported for 2022 q3
SEC form 8
2022-08-11 00:00 ET
Agile Therapeutics reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Agile Therapeutics reported for 2022 q2
SEC form 10
2022-05-12 00:00 ET
Agile Therapeutics reported for 2022 q1
SEC form 8
2022-03-30 00:00 ET
Agile Therapeutics published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
Agile Therapeutics published news for 2021 q4
SEC form 8
2021-11-02 00:00 ET
Agile Therapeutics published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Agile Therapeutics published news for 2021 q3
SEC form 10
2021-07-26 00:00 ET
Agile Therapeutics published news for 2021 q2
SEC form 10
2021-05-04 00:00 ET
Agile Therapeutics published news for 2021 q1